Anti-CD20 monoclonal antibody therapy in Epstein-Barr virus-associated B cell lymphoma following lung transplantation

Journal of Heart and Lung Transplantation

Volumn 19, Issue 5, 2000, Pages 492-495

  Reynaud Gaubert, Martine ^a   Stoppa, Anne Marie ^a   Gaubert, Jean Yves ^a   Thomas, Pascal ^a   Fuentes, Pierre ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY CD 20; RITUXIMAB; UNCLASSIFIED DRUG; VALACICLOVIR;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EPSTEIN BARR VIRUS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MALE; NASOPHARYNX TUMOR; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, CD20; BIOPSY; BURKITT LYMPHOMA; DNA, VIRAL; DRUG THERAPY, COMBINATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034112858     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(00)00087-5     Document Type: Article

References (23)

1. Armitage J.M., Kormos R.L., Stuart R.S., et al. Post-transplant lymphoproliferative disease in thoracic organ transplant patients Ten years of cyclosporine-based immunosuppression . J Heart Lung Transplant. 10:1991;877-887.
2. Hanto D.W., Frizzera G., Gajl-Peczalska K.J., Simmons R.L. Epstein-Barr virus, immunodeficiency, and B cell proliferation. Transplantation. 39:1985;461-472.
3. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal OKT3 in cardiac transplant recipients. N Engl J Med. 323:1990;1723-1728.
4. Craig F.E., Gulley M.L., Banks P.M. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol. 99:1993;265-276.
5. Zangwill S.D., Hsu D.T., Kichuk M.R., et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant. 17:1998;1161-1166.
6. Harwood J.S., Gould F.K., McMaster A., et al. Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation. Pediatr Transplant. 3:1999;100-103.
7. Straus S.E., Cohen J.I., Tosato G., Meier J. Epstein-Barr virus infection Biology, pathogenesis, and management . Ann Intern Med. 118:1993;45-58.
8. Mozzanica N., Cattaneo A., Fracchiolla N., et al. Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction of immunosuppression. J Heart Lung Transplant. 16:1997;964-968.
9. Pirsch J.D., Stratta R.J., Sollinger H.W., et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir two cases after solid organ transplantation . Am J Med. 86:1989;241-244.
10. Gross T.G., Hinrichs S.H., Winner J., et al. Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low dose chemotherapy. Ann Oncol. 9:1989;339-340.
11. Balfour I.C., Wall D., Luisiri A., Sotelo C., Gross T.G. Cyclophosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease. J Heart Lung Transplant. 18:1999;492-495.
12. Faro A., Kurland G., Michaels M.G., et al. Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder. Am J Respir Crit Care Med. 153:1996;1442-1447.
13. Cantarovich M., Barkun J.S., Forbes R.D.C., et al. Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin. Clin Transplant. 12:1998;109-115.
14. Fisher A., Blanche S., Le Bidois J., et al. Anti-B-cell monoclonal antibody in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 324:1991;1451-1456.
15. Benkerrou M., Jais J.P., Leblond V., et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder prognostic factors and long-term outcome . Blood. 92:1998;3137-3147.
16. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., et al. IDEC-C2B8 results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma . J Clin Oncol. 15:1997;3266-3274.
17. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patient with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
18. Nguyen D.T., Amess J.A., Doughty H., et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low grade non-Hodgkin's lymphoma and lymphoproliferative disorders evaluation of response on 48 patients . Eur J Haematol. 62:1999;76-82.
19. Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma a multicenter phase II study . Blood. 92:1998;1927-1932.
20. Davis T.A., Czerwinski D.K., Levy R. Therapy of B-cell Lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 5:1999;611-615.
21. Faye A., Van Den Abeele T., Peuchmaur M., et al. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet. 352:1998;1285.
22. Green M. Preemptive therapy Epstein-Barr virus . Transpl Proc. 28:(suppl 2):1996;5-6.
23. Savoie A., Perpete C., Carpentier L., et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood. 83:1994;2715-2722.